The CFA is committed to improving the lives of those who live with and are affected by Fabry disease in Canada.
The Phase I Gene Therapy Study for Fabry Disease is looking to recruit interested patients. This is a first-in-human study for the treatment of Fabry disease.
In the 16-week clinical trials expected to start later this year — if the research method is given the nod by the QE II’s ethics committee — the researchers led by West and Khan will measure the effects of the drug apabetalone on 44 patients suffering with Fabry disease.
The Board is responsible for the highest level of decision-making and communicates the organization’s vision to all members and the community.
WHO WE ARE
The CFA encourages and supports research into the causes, treatment and management of Fabry disease, but most importantly arranges for, coordinates and increases the facilities available for diagnosis, consultation and treatment of those suffering from Fabry disease.
The CFA is a small group of patients and their families that have gathered together to support and assist others in the community across Canada. If you have Fabry, or know someone affected by the disease, we hope that you will consider getting involved.
We are committed to improving the lives of those who live with and are affected by Fabry disease in Canada.
Subscribe error, please review your email address.
You're now subscribed, thank you!
There was a problem with your submission. Please check the field(s) with red label below.
Your message has been sent. We'll get back to you soon!